The MFDS reviews clinical data for drug registration by evaluating study design, methodologies, and results to ensure scientific rigor and validity. It assesses safety and efficacy data from preclinical and clinical trials, considering potential risks and benefits. The MFDS may request additional... Read More
The process for submitting a New Drug Application (NDA) to the MFDS involves preparing a comprehensive dossier that includes clinical trial data, safety and efficacy information, and manufacturing details. Applicants must submit the NDA electronically, after which the MFDS conducts a thorough... Read More
The MFDS ensures the safety of new drugs in South Korea through a comprehensive evaluation process that includes clinical trials, risk assessments, and safety monitoring. It reviews data on drug efficacy and potential side effects before approval, mandates post-marketing surveillance, and requires... Read More
The Pharmaceutical Affairs Act in South Korea establishes the regulatory framework for the approval, manufacture, distribution, and safety of pharmaceuticals. It aims to ensure the efficacy and safety of drugs, mandating rigorous evaluation processes for new products and enforcing compliance with quality... Read More
Drug registration in South Korea is governed primarily by the Pharmaceutical Affairs Act, which outlines the approval process, safety standards, and quality control measures. Additional regulations include the Bioethics and Safety Act and the Korean Good Manufacturing Practice (GMP) guidelines, ensuring compliance... Read More
The MFDS regulates pharmaceutical products in South Korea through a comprehensive framework involving pre-market approval, rigorous safety and efficacy evaluations, and compliance inspections. It monitors manufacturing practices, enforces labeling requirements, and conducts post-market surveillance to ensure ongoing safety. The MFDS also provides... Read More
The Ministry of Food and Drug Safety (MFDS) in South Korea oversees drug registration by evaluating safety, efficacy, and quality of pharmaceuticals. It conducts thorough assessments and inspections, ensuring compliance with regulations. The MFDS also facilitates market access, monitors post-market safety, and... Read More
In Taiwan, drug sponsors are responsible for submitting applications for approval, ensuring clinical trial compliance with TFDA guidelines, and maintaining Good Manufacturing Practice (GMP) standards. They must also monitor the drug’s safety through post-market surveillance, submit Periodic Safety Update Reports (PSURs), and... Read More
In Taiwan, off-label drug use is regulated by the TFDA, allowing it when no approved alternatives exist or standard treatments fail. Physicians must provide medical justification and obtain informed consent from patients. The TFDA monitors off-label use through post-market surveillance, ensuring patient... Read More
In Taiwan, drug patents are managed under a patent linkage system, ensuring that generic drug approval is aligned with patent protections. During registration, innovators list patents with the TFDA, and generics cannot be approved until the patents expire or are legally challenged.... Read More